Madrigal Pharmaceuticals, Inc.
MDGL
$546.66
$12.502.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 17.00% | -3.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.00% | -3.04% | |||
| Cost of Revenue | 49.02% | 9.81% | |||
| Gross Profit | 13.97% | -4.09% | |||
| SG&A Expenses | 7.77% | 11.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.08% | 6.14% | |||
| Operating Income | 39.27% | -55.55% | |||
| Income Before Tax | 38.62% | -61.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 38.62% | -61.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 38.62% | -61.15% | |||
| EBIT | 39.27% | -55.55% | |||
| EBITDA | 39.43% | -55.93% | |||
| EPS Basic | 22.76% | -26.71% | |||
| Normalized Basic EPS | 22.76% | -26.71% | |||
| EPS Diluted | 22.76% | -26.71% | |||
| Normalized Diluted EPS | 22.76% | -26.71% | |||
| Average Basic Shares Outstanding | -20.53% | 27.17% | |||
| Average Diluted Shares Outstanding | -20.53% | 27.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||